Heron Therapeutics (HRTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

HRTX Heron Therapeutics

Watchlist

3.050
-0.050-1.61%

Close Jul 26 16:00 ET

3.060
+0.010+0.33%

Post 18:48 ET

459.49MMarket Cap-5545P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

While Shareholders of Heron Therapeutics (NASDAQ:HRTX) Are in the Black Over 1 Year, Those Who Bought a Week Ago Aren't so Fortunate
Yahoo FinanceJul 25 07:12 ET
Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
MT NewswiresJul 15 08:40 ET
Express News | Heron Therapeutics Announces ZYNRELEF Included In Proposed 2025 Non-Opioid Policy For Pain Relief Under Medicare OPPS And ASC Payment Systems; Effective April 1, 2025; CMS Issued Proposed Rule Based On ZYNRELEF's Postoperative Pain Indication And...
BenzingaJul 15 08:03 ET
Express News | Heron Therapeutics Announces the Inclusion of Zynrelef® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the Opps and the Asc Payment System
ReutersJul 15 08:00 ET
Breakeven On The Horizon For Heron Therapeutics, Inc. (NASDAQ:HRTX)
Simply Wall StJul 12 10:29 ET
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Yahoo FinanceJul 11 12:00 ET

Comments

Trytosaveabit

Jul 15 07:43

Update

$Heron Therapeutics(HRTX.US)$ Heron Therapeutics Says Non-Opioid Pain Medication to Be Included in Proposed Medicare Programs
MT Newswires· 2 mins ago
Heron Therapeutics (HRTX) said Monday that its drug Zynrelef is included as a non-opioid pain medicine in proposed 2025 Medicare programs.
Zynrelef will be included under Medicare's Outpatient Prospective Payment System and the Medicare Ambulatory Surgical Center, beginning April 1.
The company said Zynrelef was qualified because it is appro...

Trytosaveabit

Jul 2 07:02

Make a note

$Heron Therapeutics(HRTX.US)$ Heron Therapeutics Inc - U.S. Food and Drug Administration ("FDA") Assigned a Prescription Drug User Fee Act ("Pdufa") Goal Date of September 23, 2024

Trytosaveabit

May 29 07:07

Watching for answer!

$Heron Therapeutics(HRTX.US)$ Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for Zynrelef® Vial Access Needle ("Van")

Jaguar8

May 29 07:05

NEWS

$Heron Therapeutics(HRTX.US)$
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...

Moomoo AI

Mar 14 10:41

Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.

Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 88%, Even After 21% Gain This Past Week

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

HRTX Heron Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target